SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chirodoc who wrote (2545)7/4/1998 9:56:00 PM
From: jmt  Read Replies (1) of 5402
 
>>>valuation is very difficult in biotech. the value of a company cannot be assess by price/earnings or price to sales because their aren't any.<<<<

Your comments are correct. Per the statement above, the value is still earnings as perceived in the future. But there are so many questions of any valuation model that diminish the precise nature of mathematics with subjective estimates of future earnings or cash flow. Even biotech models must first be driven by the viability of the science before mathematics. Who can say at this point what the future revenue may be, the competition when and/or if it comes to market.

My scientific model using P/E, FCF, DDM, EVA, MVA and BVD's tells me if the product doesn't get FDA approval it is currently overvalued. And if the product does get FDA approval it is currently undervalued. The right price is driven by supply, demand, and investor perception.

jmt
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News